ERBA Diagnostics Company Profile (NYSEMKT:ERB)

About ERBA Diagnostics (NYSEMKT:ERB)

ERBA Diagnostics logoERBA Diagnostics, Inc., through its subsidiaries, develops, manufactures and markets diagnostic test kits, or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology and diabetes testing. The Company's segments include Domestic and European. The domestic region contains its subsidiaries located in the United States and in Latin American and corporate operations. The European region contains its subsidiary located in Italy. Its tests are based on a range of technologies, including Enzyme Linked ImmunoSorbent Assay (ELISA) technology, clinical chemistry, hematology and cell separation, as well as high performance liquid chromatography (HPLC) separations, all of which are clinical testing methodologies used across the world. It also designs and manufactures laboratory instruments that perform the tests.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:ERB
  • CUSIP: N/A
  • Web: erbadiagnostics.com
Average Prices:
  • 50 Day Moving Avg: $0.50
  • 200 Day Moving Avg: $0.51
  • 52 Week Range: $0.47 - $1.19
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.50
  • P/E Growth: 0.00
Profitability:
  • Net Margins: -9.30%
  • Return on Equity: -13.27%
  • Return on Assets: -8.83%
Misc:
  • Beta: 0.62
 
Frequently Asked Questions for ERBA Diagnostics (NYSEMKT:ERB)

What is ERBA Diagnostics' stock symbol?

ERBA Diagnostics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "ERB."

How were ERBA Diagnostics' earnings last quarter?

ERBA Diagnostics Inc (NYSEMKT:ERB) released its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.01) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.01. The firm had revenue of $5.90 million for the quarter, compared to the consensus estimate of $5.16 million. ERBA Diagnostics had a negative net margin of 9.30% and a negative return on equity of 13.27%. View ERBA Diagnostics' Earnings History.

Who are some of ERBA Diagnostics' key competitors?

Who are ERBA Diagnostics' key executives?

ERBA Diagnostics' management team includes the folowing people:

  • Suresh H. Vazirani, Executive Chairman of the Board
  • Hayden Jeffreys, Interim Chief Executive Officer, Director
  • Chandra Krishnan, Senior Vice President - Global Sales, Marketing and Business Development
  • Nikhil Vazirani, Director
  • Gerald E. Gallwas, Independent Director
  • David M. Templeton, Independent Director

How do I buy ERBA Diagnostics stock?

Shares of ERBA Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ERBA Diagnostics' stock price today?

One share of ERBA Diagnostics stock can currently be purchased for approximately $0.50.


MarketBeat Community Rating for ERBA Diagnostics (NYSEMKT ERB)
Community Ranking:  1.6 out of 5 ()
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  13 (Vote Underperform)
Total Votes:  19
MarketBeat's community ratings are surveys of what our community members think about ERBA Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ERBA Diagnostics (NYSEMKT:ERB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for ERBA Diagnostics (NYSEMKT:ERB)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for ERBA Diagnostics (NYSEMKT:ERB)
Earnings by Quarter for ERBA Diagnostics (NYSEMKT:ERB)
Earnings History by Quarter for ERBA Diagnostics (NYSEMKT ERB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/5/2015Q215($0.02)($0.01)$5.16 million$5.90 millionViewN/AView Earnings Details
5/18/2015Q115$0.01($0.01)$8.10 million$12.60 millionViewN/AView Earnings Details
8/12/2014Q214$0.01$6.74 million$7.54 millionViewN/AView Earnings Details
11/14/2012Q312($0.01)$4.06 million$3.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ERBA Diagnostics (NYSEMKT:ERB)
Current Year EPS Consensus Estimate: $-0.06 EPS
Next Year EPS Consensus Estimate: $-0.04 EPS

Dividends

Dividend History for ERBA Diagnostics (NYSEMKT:ERB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ERBA Diagnostics (NYSEMKT:ERB)
Insider Trades by Quarter for ERBA Diagnostics (NYSEMKT:ERB)
Insider Trades by Quarter for ERBA Diagnostics (NYSEMKT:ERB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2014Gopalkrishnan MohanCEOBuy5,000$2.89$14,450.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ERBA Diagnostics (NYSEMKT:ERB)
Latest Headlines for ERBA Diagnostics (NYSEMKT:ERB)
Source:
DateHeadline
bizjournals.com logoWorldwide $60.5 Billion Market for In Vitro Diagnostic (IVD) Tests, 2021 - Research and Markets
www.bizjournals.com - April 7 at 9:59 PM
finance.yahoo.com logoShareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against ERBA Diagnostics, Inc. and Lead Plaintiff Deadline: February 1, 2016
finance.yahoo.com - April 7 at 9:38 AM
finance.yahoo.com logoDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against ERBA Diagnostics, Inc. and Lead Plaintiff Deadline: February 1, 2016
finance.yahoo.com - April 7 at 9:38 AM
bizjournals.com logoBlood Gas and Electrolyte Analyzers Market: EME Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016-2024
www.bizjournals.com - February 17 at 5:35 PM
streetinsider.com logoERBA Diagnostics (ERBA) Names New CEO
www.streetinsider.com - November 30 at 5:03 PM
streetinsider.com logoERBA Diagnostics (ERB) Will Begin Trading OTC Under 'ERBA'
www.streetinsider.com - October 2 at 9:23 AM
biz.yahoo.com logoERBA DIAGNOSTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - September 29 at 4:50 PM
prnewswire.com logoReportLinker Review : Antinuclear Antibody Test Market by Product, Technique, Disease, End User - Forecast to 2021
www.prnewswire.com - September 27 at 9:27 AM
finance.yahoo.com logoAntinuclear Antibody Testing Market Worth USD 1,476.1 Million USD by 2021
finance.yahoo.com - September 21 at 5:22 PM
biz.yahoo.com logoERBA DIAGNOSTICS, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Ex
biz.yahoo.com - September 7 at 5:00 PM
reuters.com logoBRIEF-Erba Diagnostics announces NYSE notice of noncompliance
www.reuters.com - August 27 at 9:30 AM
prnewswire.com logoThe Worldwide Market for In Vitro Diagnostic Tests, 10th Edition
www.prnewswire.com - August 26 at 6:40 AM
reuters.com logoBRIEF-Erba Diagnostics files for non-timely 10-Q - Sec Filing
www.reuters.com - August 18 at 10:12 PM
biz.yahoo.com logoERBA DIAGNOSTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Princip
biz.yahoo.com - May 31 at 4:32 PM
finance.yahoo.com logoERBA Diagnostics, Inc. Announces Extension of CEO’S Contract Term and Appointment of Hayden Jeffreys to Board of Directors
finance.yahoo.com - May 31 at 4:15 PM
streetinsider.com logoERBA Diagnostics (ERB) Receives Notice of Noncompliance With NYSE Continued Listing Standards
www.streetinsider.com - May 21 at 2:47 PM
prnewswire.com logoBlood Gas and Electrolyte Analyzer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023
www.prnewswire.com - May 13 at 9:33 AM

Social

This page was last updated on 7/23/2017 by MarketBeat.com Staff